KLF2 and cancer: An upregulation of the MAPK/MEKK3/ERK3 pathway, and the related KLF2 and KLF4 transcription factors, have been reported to increase RhoA kinase activity in preclinical murine models of CA disease, leading to destabilization of endothelial barrier function14.